Cetuximab binds EGFR on target cells and its IgG1 Fc engages FcγR-bearing effector cells (e.g., NK cells) to trigger ADCC (and potentially CDC), killing EGFR+ cells; it also blocks EGFR signaling (anti-proliferative).